IAPIO Rec'd PCT/PTO 08 DEC 2005

FORM PTO-1390(modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTORNEY'S DOCKET NUMBER 30337 TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (IF KNOWN), SEE 37 CFR DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING 10/559925 A FILING UNDER 35 U.S.C., 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/IL2004/000477 June 3, 2004 June 9, 2003 TITLE OF INVENTION HEPARANASE ACTIVITY NEUTRALIZING ANTI- HEPARANASE MONOCLONAL ANTIBODY AND OTHER ANTI-HEPARANASE ANTIBODIES APPLICANT(S) FOR DO/EO/US Oron YACOBY-ZEEVI et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO.US) the following items and other information: 1. E This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371 3. Image: This is an express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. A copy of the International Application as filed (35 U.S.C. 371(3)(2) a. 🗵 is transmitted herewith (required only if not transmitted by the International Bureau). b. 🗵 has been transmitted by the International Bureau. c. \square is not required, as the application was filed in the United States Receiving Office (RO/US). 6. A translation of the International Application into English (35 U.S.C. 371(3)(2). 7. A copy of the International Search Report (PCT/ISA/210). 8. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3) a. \square are transmitted herewith (required only if not transmitted by the International Bureau). b. \square have been transmitted by the International Bureau. c. D have not been made; however, the time limit for making such amendments has NOT expired. d.

have not been made and will not be made. 9. A translation of the amendments to the claims under PCT Article 19(35 U.S.C. 371(c)(3)). 10. An unexecuted oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)5)). Items 13 to 18 below concern document(s) of information included: 13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. ☐ A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 16. A substitute specification. 17. \(\sigma\) A change of power of attorney and/or address letter. 18. ☐ Certificate of Mailing by Express Mail 19. In the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing 20. M Other items or information: PCT REQUEST; PRELIMINARY AMENDMENT; FLOPPY DISC WITH SEQUENCE LISTING 21. **\(\sime\)** 112 pages of specification (including Abstract page) 22. **\(\sigma\)** _ 2 pages of sequence listing tables 23. **2** 10 sheets of drawings 24. 🗷 11 pages of sequence listing 25. **E** <u>135</u> total pages

U.S. APPLICATION NO. (IF KNOWN), See 67 CFR

INTERNATIONAL APPLICATION NO. PCT/IL2004/000477

ATTORNEY'S DOCKET NUMBER

30337

THE FILING FEE HAS BEEN CALCULATED AS SHOWN BELOW:

FOR:	Column 1 No. FILED	Column 2 No. EXTRA	SMALL ENTITY		OTHER THAN A SMALL ENTITY	
	Tio. I ILLD		RATE	FEE	RATE	FEE
Basic National Stage Fee				\$ 150.00		\$ 300
National Stage Search Fee				\$ 250.00		\$ 500
National Stage Examination Fee				\$ 100.00		\$ 200
National Stage Application Size Fee (Per 50 Pages Over 100)			x \$ 125	\$ 125.00	x \$250	\$
Multiple Dependent Claim			x \$ 180	\$ 0.00	x \$ 360	\$
Total Claims*	171 – 20 =	151	x \$ 25	\$3,775.00	x \$50	\$
Independent Claims*	2 - 3 =	0	x \$100	\$ 0.00	x \$200	\$
* (If the difference in Column 1 is less than "0", enter "0" in Column 2)			TOTAL	<u>\$4400</u>	TOTAL	<u>\$</u>

Please charge my deposit account No. 50-1407 in the amount of \$4,400.

A duplicate copy of this sheet is enclosed.

- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No 50-1407. A duplicate copy of this sheet is enclosed.
 - Any additional filing fees required under 37 CFR 1.16.
 - Any patent application processing fees under 37 CFR 1.17.
- The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to deposit Account No. 50-1407. A duplicate copy of this sheet is enclosed.
 - Any patent application processing fees under 37 CFR 1.17.
 - Any filing fees under 37 CFR 1.16 for presentation of extra claims.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.